Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome (Novel Oral Anticoagulants in LATAM – Evolving Treatments ) | Physician & Payer Forum | Brazil and Mexico | 2014
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and Mexico for the treatment and prophylaxis of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF) has expanded the market landscape and given physicians alternatives to the more traditional anticoagulation strategies. Further, anticipated use of NOACs in the prevention of thrombotic episodes in acute coronary syndrome (ACS) will possibly enlarge the list of approved indications for some of these agents. However, successful uptake of NOACs depends highly on securing formulary coverage across healthcare programs in Brazil and Mexico, and the NOACs’ premium-price tag poses a major challenge to these cost-contained healthcare systems.
